Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?

Table 3

Overall survival and disease-specific survival by age and therapeutic modality, adapted from Culp et al. (2014) [13].

Age/therapeutic modality	5-year OS rate (%)	DSS rate (%)
		1 year	3 years	5 years
<70 years
NLT	28,9	86,1	57,7	45,8
RP	71,2	96,7	86,9	82,0
BT	57,4	92,2	73,9	65,2
≥70 years
NLT	18,1	80,1	58,6	49,5
RP	50,3	86,7	70,8	63,5
BT	48,5	86,2	69,9	62,5

OS: overall survival; DSS: disease-specific survival; RP: radical prostatectomy; BT: brachytherapy; NLT: no local treatment.